NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.
Becker's Hospital Review11h
16 new weight loss drugs to enter market by 2029, economists say
Competition is brewing for Novo Nordisk and Eli Lilly, two of the world's leading pharmaceutical weight loss companies, according to analysts ... The potential business rivals are Roche, Amgen, Pfizer ...
‘Dual-action’ weight-loss pill helps people drop 13% of body weight in three months in early trials
An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...
New daily pill touted for weight loss: 3 things to know
The maker of injectable weight loss drugs including Ozempic and Wegovy is touting the results of an early-stage trial that ...
Early trial shows success for daily weight loss pill: 3 things to know
The maker of injectable weight loss drugs including Ozempic and Wegovy is touting the results of an early-stage trial that ...
Experimental Weight Loss Drug Beat Ozempic and Wegovy in Early Trial
People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the average weight loss seen with semaglutide.
Weight-loss drug Zepbound may be more effective in women
The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis.
Weight-loss drugs and children: What doctors say about the safety, effectiveness of the medications
Novo Nordisk's liraglutide has been approved for children who are at least 12 years old. However, the drug is now being ...
Medscape11h
'Remarkable' Weight Loss Seen With Novel Oral Combination That Is Safe and Tolerable in Phase 1 Study
Amycretin, a dual pathway, oral weight loss drug, was found to be safe and tolerable in a phase 1 study and led to weight loss of up to 13% in people with overweight and obesity.